1Shapiro DA, Renoek S, Arrington E, et al. Aripiprazole, a novel atypi- cal antipsyehotie drug with a unique and robust pharmacology [J]. Neurupsyehopharmaeology, 2003, 28(8) : 1400-1411.
2Marder SR, McQUADE RD, Stock E, et al. Aripipruzole in the treat- ment of schizophrenia: safety and tolerability in short-term, placebo- controlled trials[J]. Schizoohrenia Res, 2003, 61(2-3) : 123-136.
3Kikuchi T, TottoriI K, Uwahodo Y, et al.7-(4-[4-(2, 3- Diehlorophenyl)-l-piperazinyl] butyloxy)-3, 4-dihydro-2( 1 H)-quino- linone( OPC-14597 ), a new putative antipsyehotie drug with both presynaptie dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity [J]. J Pharrnaeol Exp Ther, 1995, 274 (1) :329-336.
7Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripipra- zole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled compari- son with intramuscular haloperidol [J]. Psychopharmacology (Berl), 2006, 188(3) :281-292.
8Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review [J]. Clin Ther, 2010, 32 Suppl 1 : S3-20.
